Insider · CIK 0001543425
Kary Eldred
Files at GALT (GALECTIN THERAPEUTICS INC). First filing Oct 23, 2024, latest Feb 9, 2026.
Kary Eldred files SEC Form 4 as director at GALT (GALECTIN THERAPEUTICS INC). Since Oct 23, 2024, Kary Eldred has reported 6 open-market buys worth $21k and 0 open-market sells worth $0, the latest filed on Feb 9, 2026.
A track record needs three past buys with six months of prices behind them; Kary Eldred has 1, so none is measured yet.
The newest scored trade: bought $810 of GALT on Feb 6, 2026, filed Feb 9, 2026, scored 23 (weak). In the last 12 months: 3 buys worth $6,032 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GALT: GALECTIN THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | GALTbuy GALECTIN THERAPEUTICS INC | $810 300 shares | +0% | +130% from low-57% from high | |
| 16Weak | GALECTIN THERAPEUTICS INC | $2,611 700 shares | +1% | +375% from low-39% from high | |
| 31Weak | GALECTIN THERAPEUTICS INC | $2,611 700 shares | +1% | +375% from low-39% from high | |
| 27Weak | GALECTIN THERAPEUTICS INC | $2,925 1,000 shares | +2% | +226% from low-17% from high | |
| 41Moderate | GALECTIN THERAPEUTICS INC | $11k 13,469 shares | +27% | - | |
| 23Weak | GALECTIN THERAPEUTICS INC | $1,300 500 shares | +1% | - |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +300 | $2.70 | $810 | 65,682 | Feb 9, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Dec 23, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock10b5-1 | +700 | $3.73 | $2,611 | 65,382 | Dec 23, 2025 |
| Dec 23, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +700 | $3.73 | $2,611 | 65,382 | Dec 23, 2025 |
| Jul 21, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +1,000 | $2.93 | $2,925 | 64,682 | Jul 22, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 27, 2025 |
| Dec 24, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +13,469 | $0.82 | $11k | 63,682 | Dec 26, 2024 |
| Oct 23, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +500 | $2.60 | $1,300 | 50,213 | Oct 23, 2024 |
Questions about Kary Eldred
Answered from the filings on this page, as of the latest one.
Is Kary Eldred buying or selling?
In the last 12 months Kary Eldred reported 3 open-market buys worth $6,032 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $810 of GALT on Feb 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Kary Eldred's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kary Eldred has 1.
Where does Kary Eldred file Form 4?
Kary Eldred has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.